Defilade Capital Management L.P. Takes Position in Neurocrine Biosciences, Inc. $NBIX

Defilade Capital Management L.P. purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the first quarter, HoldingsChannel reports. The institutional investor purchased 209,932 shares of the company’s stock, valued at approximately $27,656,000. Neurocrine Biosciences makes up about 3.9% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 11th largest position.

Other hedge funds also recently added to or reduced their stakes in the company. Ruffer LLP bought a new stake in Neurocrine Biosciences in the 4th quarter worth about $2,479,000. Robinhood Asset Management LLC bought a new position in Neurocrine Biosciences during the 4th quarter valued at about $5,715,000. Wesbanco Bank Inc. lifted its stake in Neurocrine Biosciences by 88.9% during the 4th quarter. Wesbanco Bank Inc. now owns 17,000 shares of the company’s stock valued at $2,411,000 after acquiring an additional 8,000 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $1,866,000. Finally, Swedbank AB boosted its holdings in shares of Neurocrine Biosciences by 6.7% during the 4th quarter. Swedbank AB now owns 584,129 shares of the company’s stock valued at $82,847,000 after acquiring an additional 36,800 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
• Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 1,250 shares of Neurocrine Biosciences stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director owned 1,588 shares in the company, valued at $289,031.88. This trade represents a 44.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the sale, the director directly owned 15,860 shares of the company’s stock, valued at approximately $2,621,975.20. The trade was a 61.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 395,422 shares of company stock valued at $62,448,693 in the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $166.80 on Monday. The stock has a market capitalization of $16.77 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.70 and a beta of 0.39. The firm’s 50 day moving average price is $167.81 and its 200-day moving average price is $146.50. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several research reports. Leerink Partners boosted their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Wells Fargo & Company raised their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Wedbush lifted their target price on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. The Goldman Sachs Group assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, June 2nd. They set a “buy” rating and a $213.00 target price for the company. Finally, Guggenheim increased their price target on Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.64.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.